We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.4B
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
+26.01%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.4B
AUM Growth
+$351M
(+7%)
Cap. Flow
+$35.9M
Cap. Flow
% of AUM
0.67%
Top 10 Holdings %
Top 10 Hldgs %
42.1%
Holding
152
New
38
Increased
33
Reduced
27
Closed
23
Avg Time Held Equity + Options
6.9
quarters
Top 10 Avg Time Held Equity + Options
4.1
quarters
Top 20 Avg Time Held Equity + Options
4.5
quarters
Avg Time Held Equity only
7.4
quarters
Top 10 Avg Time Held Equity only
4.4
quarters
Top 20 Avg Time Held Equity only
4.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$59.7M |
| 2 |
Odyssey Therapeutics
ODTX
|
+$52.6M |
| 3 |
Arcutis Biotherapeutics
ARQT
|
+$47.6M |
| 4 |
Cogent Biosciences
COGT
|
+$47.6M |
| 5 |
Humana
HUM
|
+$46.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$54.7M |
| 2 |
Danaher
DHR
|
+$50.4M |
| 3 |
Enliven Therapeutics
ELVN
|
+$50.2M |
| 4 |
Boston Scientific
BSX
|
+$48.8M |
| 5 |
Disc Medicine
IRON
|
+$48.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.03% |
| 2 | Miscellaneous | 2.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
Alnylam Pharmaceuticals
ALNY
$30.1B
| $5.12M | 0.09% |
17,000
-102,000
| -86% | -$30.8M |
2024 Q2
8 quarters
|
|
102
Palisade Bio
PALI
$249M
| $4.88M | 0.09% |
2,333,000
| – | – |
2025 Q4
2 quarters
|
|
103
DELISTED
AtaiBeckley Inc
ATAI
| $4.2M | 0.08% |
797,500
+450,500
| +130% | +$1.9M |
2026 Q1
1 quarter
|
|
|
104
CALL
UnitedHealth
UNH
$349B
| $4.16M | 0.08% |
+10,000
| New | +$3.71M |
2026 Q2
0 quarters
|
|
105
PTC Therapeutics
PTCT
$5.02B
| $4.01M | 0.07% |
49,100
| – | – |
2025 Q4
2 quarters
|
|
106
Artivion
AORT
$1.04B
| $3.93M | 0.07% |
175,000
+24,000
| +16% | +$671K |
2026 Q1
1 quarter
|
|
107
CALL
Elevance Health
ELV
$92.2B
| $3.87M | 0.07% |
+10,000
| New | +$3.71M |
2026 Q2
0 quarters
|
|
108
Neumora Therapeutics
NMRA
$66.3M
| $3.64M | 0.07% |
+2,139,882
| New | +$4.07M |
2026 Q2
0 quarters
|
|
109
Acadia Pharmaceuticals
ACAD
$3.29B
| $3.47M | 0.06% |
+137,000
| New | +$3.01M |
2026 Q2
0 quarters
|
|
110
Amylyx Pharmaceuticals
AMLX
$3.45B
| $3.29M | 0.06% |
+183,400
| New | +$2.84M |
2026 Q2
0 quarters
|
|
111
Tyra Biosciences
TYRA
$1.28B
| $3.26M | 0.06% |
+102,000
| New | +$3.37M |
2026 Q2
0 quarters
|
|
112
Rapport Therapeutics
RAPP
$1.39B
| $3.19M | 0.06% |
+76,616
| New | +$2.82M |
2026 Q2
0 quarters
|
|
113
AgomAb Therapeutics NV
AGMB
$432M
| $2.5M | 0.05% |
+192,740
| New | +$2.17M |
2026 Q2
0 quarters
|
|
114
Tarsus Pharmaceuticals
TARS
$3.39B
| $2.24M | 0.04% |
+35,581
| New | +$2.27M |
2026 Q2
0 quarters
|
|
115
Aclaris Therapeutics
ACRS
$503M
| $2.23M | 0.04% |
+421,500
| New | +$1.88M |
2026 Q2
0 quarters
|
|
116
Cytokinetics
CYTK
$8.66B
| $2.2M | 0.04% |
+25,800
| New | +$1.85M |
2026 Q2
0 quarters
|
|
117
InspireMD
NSPR
$22.7M
| $2.19M | 0.04% |
3,133,405
| – | – |
2023 Q2
12 quarters
|
|
118
Ocular Therapeutix
OCUL
$1.59B
| $2.16M | 0.04% |
+220,000
| New | +$1.99M |
2026 Q2
0 quarters
|
|
119
Evommune Inc
EVMN
$212M
| $2.14M | 0.04% |
+161,000
| New | +$3.74M |
2026 Q2
0 quarters
|
|
120
Belite Bio
BLTE
$6.21B
| $2.05M | 0.04% |
+13,300
| New | +$2.04M |
2026 Q2
0 quarters
|
|
121
Ovid Therapeutics
OVID
$418M
| $2.01M | 0.04% |
+747,000
| New | +$1.93M |
2026 Q2
0 quarters
|
|
122
Eupraxia Pharmaceuticals
EPRX
$449M
| $1.78M | 0.03% |
+269,000
| New | +$1.85M |
2026 Q2
0 quarters
|
|
123
PUT
SELLAS Life Sciences
SLS
$2.48B
| $1.37M | 0.03% |
+92,500
| New | +$639K |
2026 Q2
0 quarters
|
|
124
Traws Pharma
TRAW
$6.3M
| $1.01M | 0.02% |
1,203,260
+597,729
| +99% | +$824K |
2024 Q2
8 quarters
|
|
125
ADC Therapeutics
ADCT
$211M
| – | – |
-1,318,026
| Closed | -$4.94M | – |
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q2 2026 Portfolio in Review
As of Q2 2026, OrbiMed held 152 positions worth $5.4B, up 7% from $5.05B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
OrbiMed's Q2 2026 filing shows 38 new, 33 increased, 27 reduced and 23 closed positions. Its largest new stake was UnitedHealth: 161,100 shares worth $67M. The largest sale was Pfizer, an estimated $54.7M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier, followed by Miscellaneous.
- OrbiMed's largest Q2 2026 buy was UnitedHealth: 161,100 shares worth $67M.
- OrbiMed added most to Cogent Biosciences in Q2 2026, an estimated $47.6M increase.
- OrbiMed's biggest Q2 2026 reduction was Enliven Therapeutics, cutting an estimated $50.2M.
- OrbiMed fully exited Pfizer in Q2 2026, selling an estimated $54.7M.
- OrbiMed's ten largest holdings make up 42% of its $5.4B portfolio in Q2 2026.
- OrbiMed opened 38 new positions and closed 23 in Q2 2026.
- OrbiMed's portfolio value rose 7% quarter-over-quarter to $5.4B.
Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.